Published in World J Gastrointest Oncol on October 15, 2016
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
The Hedgehog and Wnt signalling pathways in cancer. Nature (2001) 9.19
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature (2004) 7.21
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Tissue repair and stem cell renewal in carcinogenesis. Nature (2004) 6.28
Gastric cancer originating from bone marrow-derived cells. Science (2004) 6.04
Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer (2006) 5.75
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Cancer stem cells: current status and evolving complexities. Cell Stem Cell (2012) 5.07
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A (2008) 4.60
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 4.21
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One (2008) 3.97
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Cancer stem cells in solid tumors. Curr Opin Biotechnol (2007) 3.91
CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest (2010) 3.60
Telomerase and cancer therapeutics. Nat Rev Cancer (2008) 3.46
Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med (1998) 3.42
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal (1997) 2.77
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res (2010) 2.50
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control (2003) 2.46
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology (2008) 2.12
Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest (1994) 1.93
MicroRNA regulation of cancer stem cells. Cancer Res (2011) 1.84
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer (2008) 1.75
Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene (2007) 1.67
The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 1.66
Angiogenesis--a new target for future therapy. Vascul Pharmacol (2006) 1.65
Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm (2002) 1.52
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 1.45
Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev (2012) 1.40
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology (2010) 1.36
Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology (2010) 1.34
Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One (2011) 1.30
Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene (2005) 1.25
Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol (2006) 1.25
Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem Cells (2009) 1.24
Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis (2011) 1.20
RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci (2011) 1.19
Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One (2012) 1.19
Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol (2005) 1.18
Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis (2014) 1.17
An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res (2009) 1.16
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother (2011) 1.03
The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Mol Med Rep (2012) 0.99
Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release (2009) 0.99
CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials (2012) 0.96
Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol (2014) 0.92
Angiogenesis in cancer - general pathways and their therapeutic implications. J BUON (2014) 0.92
New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine (Lond) (2006) 0.91
Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget (2016) 0.91
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond) (2010) 0.91
The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther (2013) 0.89
Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice. J Mol Med (Berl) (2014) 0.87
Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials (2013) 0.87
Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int J Nanomedicine (2012) 0.87
Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine (2011) 0.87
Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release (2010) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer. Oncol Res Treat (2014) 0.85
CD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer. Oncogene (2014) 0.85
The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials (2014) 0.84
Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int (2006) 0.81
Nanomedicine-mediated cancer stem cell therapy. Biomaterials (2015) 0.81
The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget (2016) 0.81
iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine (Lond) (2015) 0.81
Inhibition of tankyrase 1 in human gastric cancer cells enhances telomere shortening by telomerase inhibitors. Oncol Rep (2010) 0.80
Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach. Expert Opin Drug Deliv (2015) 0.79
Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer. Clin Colorectal Cancer (2015) 0.79
Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int (2015) 0.79
Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. Biomaterials (2015) 0.78
Salinomycin inhibits the growth of colorectal carcinoma by targeting tumor stem cells. Oncol Rep (2015) 0.78
Notch regulation of gastrointestinal stem cells. J Physiol (2016) 0.78
Metabolic Modification in Gastrointestinal Cancer Stem Cells: Characteristics and Therapeutic Approaches. J Cell Physiol (2016) 0.77
Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine. Cancer Lett (2016) 0.76
EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA. Biomacromolecules (2015) 0.76